Sanofi Translates its mRNA interest into big bucks
Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
AACR 2021 – still awaiting validation, Sanofi keeps on buying
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Translate’s investment case shifts fully to Covid-19
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
Ionis joins the inhaled cystic fibrosis therapy race
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
The next triggers in Covid-19 vaccine development
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
Moderna shows the value of bulk-buying
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
